# Celleration

Startup profile on Capital Atlas: https://capitalatlas.ai/startups/celleration

- Industry: Medical Devices & Equipment
- Headquarters: Eden Prairie, US
- Website: www.celleration.com
- Total disclosed funding: $65M
- Latest round: Series A (Jan 4, 2013)
- Investors on record: 17

## About

Celleration, Inc. specializes in digital solutions for small to medium-sized enterprises, offering tools for streamlining online operations, enhancing customer engagement, and improving sales processes.Founded in 1999 and headquartered in Eden Prairie, US, Celleration, Inc. focuses on providing integrated digital platforms for online businesses. In February 2015, Celleration was acquired by Alliqua BioMedical for USD 30.4 mn. The company has engaged in a total of 6 deals to date, with its most recent deal occurring on February 3, 2015. The founder's history and prior ventures are not publicly available.Celleration, Inc. primarily offers a suite of digital solutions designed to streamline online business operations for small to medium-sized enterprises. Their core product is an integrated platform that combines website hosting, domain registration, and e-commerce functionality, allowing businesses to establish and manage a robust online presence. These services cater to a diverse clientele, including entrepreneurs, startups, and established businesses looking to expand their digital footprint. The platform enables users to seamlessly create websites, manage online stores, and engage with customers through various digital marketing tools. This offering has been developed to resolve challenges related to online visibility, customer engagement, and sales conversion rates across multiple industries, and is sold mainly in North America and select markets in Europe and Asia.Celleration, Inc. generates its revenue primarily through a subscription-based model, where clients pay for access to various tiers of services that include hosting, domain management, and e-commerce capabilities. Businesses may choose from different subscription plans that provide varying levels of service, ensuring a consistent revenue stream for the company. Additionally, transactional services such as domain registration and online payment processing further enhance revenue generation. These transactions occur directly between Celleration and its clients, emphasizing a Business-to-Business (B2B) approach that fosters growth in recurring revenue.With the recent acquisition in 2015, Celleration is poised to explore new growth avenues under Alliqua BioMedical. Specific upcoming products or features have not been detailed, but the company is expected to leverage its existing technologies to enhance service offerings. Future market expansions are likely to focus on enhanced penetration in North America, Europe, and Asia, aligning with the parent company's strategic objectives.

## Funding rounds

- Series A, Jan 4, 2013, $6.4M — Baird Capital Partners, Venture Investors, New Science Ventures
- Series E, Jan 7, 2011, $8M — CID Capital, Baird Capital Partners, Prism Venture Management, Venture Investors, St. Paul Venture Capital, Triathlon Medical Partners, SightLine Partners, Seneca Partners, Affinity Ventures, AAVIN, CHV Capital, New Science Ventures
- Series D, Jun 18, 2008, $4.9M — CID Capital, Baird Capital Partners, Venture Investors, St. Paul Venture Capital, Triathlon Medical Partners, Seneca Partners, Affinity Ventures, Heron Capital, AAVIN, CHV Capital, New Science Ventures, Tyco Sigma Limited, HMA Capital
- Series D, Apr 17, 2008, $25M — CID Capital, Baird Capital Partners, Venture Investors, Affinity Capital Management, St. Paul Venture Capital, Prism Capital, Triathlon Medical Partners, Seneca Partners, AAVIN, New Science Ventures
- Series C, Nov 1, 2005, $21M — CID Capital, Baird Capital Partners, Prism Venture Management, Venture Investors, St. Paul Venture Capital, Triathlon Medical Partners, Seneca Partners, Affinity Ventures, AAVIN, New Science Ventures

## Investors

- CID Capital (https://capitalatlas.ai/funds/cid-capital) — Series C, Series D, Series E
- Baird Capital Partners (https://capitalatlas.ai/funds/baird-capital-partners) — Series C, Series D, Series E, Series A
- Prism Venture Management (https://capitalatlas.ai/funds/prism-venture-management) — Series C, Series E
- Venture Investors — Series C, Series D, Series E, Series A
- St. Paul Venture Capital (https://capitalatlas.ai/funds/st-paul-venture-capital) — Series C, Series D, Series E
- Triathlon Medical Partners (https://capitalatlas.ai/funds/triathlon-medical-partners) — Series C, Series D, Series E
- Seneca Partners — Series C, Series D, Series E
- Affinity Ventures — Series C, Series D, Series E
- AAVIN (https://capitalatlas.ai/funds/aavin) — Series C, Series D, Series E
- New Science Ventures (https://capitalatlas.ai/funds/new-science-ventures) — Series C, Series D, Series E, Series A
- Affinity Capital Management (https://capitalatlas.ai/funds/affinity-capital-management) — Series D
- Prism Capital (https://capitalatlas.ai/funds/prism-capital) — Series D
- Heron Capital (https://capitalatlas.ai/funds/heron-capital) — Series D
- CHV Capital (https://capitalatlas.ai/funds/chv-capital) — Series D, Series E
- Tyco Sigma Limited — Series D
- HMA Capital (https://capitalatlas.ai/funds/hma-capital) — Series D
- SightLine Partners — Series E